Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Glioblastoma 3Neuroblastoma 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Advanced Malignant Solid Tumor 2Thymoma 1Retinoblastoma 1Resectable Pancreatic Cancer 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Objective Response Rate 1Neoplasm Metastasis 1Myasthenia Gravis 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Hepatoblastoma 1Glioma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Advanced Refractory Solid Tumors 1

Interventions

spartalizumab 1Immunotherapy 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Objective Response Rate × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT05760196 2023-03-08

Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors

Renmin Hospital of Wuhan University

Phase 2 Unknown
56 enrolled

Objective Response Rate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡